Erratum: Expression of Concern: Influence of the PNPLA3 rs738409 Polymorphism on NonAlcoholic Fatty Liver Disease and Renal Function among Normal Weight Subjects (PLoS ONE (2015) 10:7 (e0132640) DOI: 10.1371/journal.pone.0132640);Influence of the PNPLA3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Oniki, Kentaro ^a   Saruwatari, Junji ^a   Izuka, Tomoko ^a   Kajiwara, Ayami ^a   Morita, Kazunori ^a   Sakata, Misaki ^a   Otake, Koji ^b   Ogata, Yasuhiro ^b   Nakagawa, Kazuko ^a,c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; OBESITY; PATATIN LIKE PHOSPHOLIPASE 3 GENE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-SECTIONAL STUDY; GENETIC PREDISPOSITION; GENETICS; JAPAN; KIDNEY FUNCTION TEST; SINGLE NUCLEOTIDE POLYMORPHISM;

ADIPONUTRIN, HUMAN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLOMERULAR FILTRATION RATE; HUMANS; JAPAN; KIDNEY FUNCTION TESTS; LIPASE; LONGITUDINAL STUDIES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OVERWEIGHT; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 84941313453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0279460     Document Type: Erratum

References (37)

1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10: 330-344. doi:10.1038/nrgastro.2013.41PMID: 23507799.
2. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014; 59: 1174-1197. doi:10.1002/hep.26717 PMID: 24002776.
3. Fung J, Lee CK, Chan M, Seto WK, Lai CL, Yuen MF. High prevalence of non-alcoholic fatty liver disease in the Chinese-results from the Hong Kong liver health census. Liver Int. 2015; 35: 542-549. doi:10.1111/liv.12619 PMID: 24923704.
4. Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2015; 41: 65-76. doi:10.1111/apt.13012 PMID: 25376360.
5. Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol. 2012; 27: 1555-1560. doi:10.1111/j.1440-1746.2012.07222.x PMID: 22741595.
6. Feng RN, Du SS, Wang C, Li YC, Liu LY, Guo FC, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol. 2014; 20: 17932-17940. doi:10.3748/wjg.v20.i47.17932 PMID: 25548491.
7. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363: 157-163. PMID: 14726171.
8. Zhang L, You W, Zhang H, Peng R, Yao A, Li X, et al. PNPLA3 Polymorphisms (rs738409) and Non- Alcoholic Fatty Liver Disease Risk and Related Phenotypes: A Meta-Analysis. J Gastroenterol Hepatol. 2015; doi:10.1111/jgh.12889.
9. Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol. 2013; 10: 645-655. doi:10.1038/nrgastro.2013.182PMID: 24061205.
10. Shen JH, Li YL, Li D, Wang NN, Jing L, Huang YH. Thers738409 (I148M) variant of the PNPLA3 gene and cirrhosis: A meta-analysis. J Lipid Res. 2015; 56: 167-175. doi:10.1194/jlr.M048777 PMID: 25378656.
11. Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: A meta-analysis. Am J Gastroenterol. 2014; 109: 325-334. doi:10.1038/ajg.2013.476PMID: 24445574.
12. Shen J, Wong GL, Chan HL, Chan HY, Yeung DK, Chan RS, et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther. 2014; 39: 532-539. doi:10.1111/apt.12609 PMID: 24417250.
13. Zhang Y, Cai W, Song J, Miao L, Zhang B, Xu Q, et al. Association between the PNPLA3 I148M polymorphism and non-alcoholic fatty liver disease in the Uygur and Han ethnic groups of northwestern China. PLoS One. 2014; 9: e108381. doi:10.1371/journal.pone.0108381 PMID: 25290313.
14. Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem. 2011; 286: 37085-37093. doi 10.1074/jbc.M111.290114 PMID: 21878620.
15. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al. Association of nonalcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis. PLoS Med. 2014; 11: e1001680. doi:10.1371/journal.pmed.1001680 PMID: 25050550.
16. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: The roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol. 2010; 21: 406-412. doi:10.1681/ASN.2009080820 PMID: 20150538.
17. Machado MV, Goncalves S, Carepa F, Coutinho J, Costa A, Cortez-Pinto H. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int. 2012; 32: 241-248. doi:10.1111/j.1478-3231.2011.02623.x PMID: 22098270.
18. Musso G, Cassader M, Gambino R. PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in NAFLD. Hepatology. 2014; doi:10.1002/hep.27643.
19. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012; 142: 1592-1609. doi10.1053/j.gastro.2012.04.001 PMID: 22656328.
20. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005; 22: 1141-1145. PMID: 16108839.
21. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009; 7: 1104- 1112. doi:10.1016/j.cgh.2009.05.033 PMID: 19523535.
22. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 982-992. doi:10.1053/j.ajkd.2008.12.034 PMID: 19339088.
23. Hotta K, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet. 2010; 11: 172. doi:10.1186/1471-2350-11-172 PMID: 21176169.
24. Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One. 2012; 7: e38322. doi:10.1371/journal.pone.0038322 PMID: 22719876.
25. Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet. 2013; 132: 783-792. doi:10.1007/s00439-013-1294-3 PMID: 23535911.
26. Huang Y, He S, Li JZ, Seo YK, Osborne TF, Cohen JC, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A. 2010; 107: 7892-7897. doi:10.1073/pnas.1003585107 PMID: 20385813.
27. Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol. 2013; 19: 6969-6978. doi:10.3748/wjg.v19.i41.6969 PMID: 24222941.
28. Kim NH, Kim JH, Kim YJ, Yoo HJ, Kim HY, Seo JA, et al. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver Int. 2014; 34: 604-611. doi:10.1111/liv.12454 PMID: 24382309.
29. Hyysalo J, Gopalacharyulu P, Bian H, Hyotylainen T, Leivonen M, Jaser N, et al. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity. Diabetes. 2014; 63: 312-322. doi:10.2337/db13-0774 PMID: 24009255.
30. Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedfalk K, Mancina RM, et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet. 2014; 23: 4077-4085. doi:10.1093/hmg/ddu121PMID: 24670599.
31. Romeo S, Dongiovanni P, Petta S, Pihalajamaki J, Valenti L. PNPLA3 I148M genetic variant and kidney disease. Hepatology. 2014; doi:10.1002/hep.27642.
32. Petta S, Valenti L, Marchesini G, Di Marco V, Licata A, Camma C, et al. PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. PLoS One. 2013; 8: e74089. doi:10.1371/journal.pone.0074089 PMID: 24069270.
33. Shen J, Wong GL, Chan HL, Chan RS, Chan HY, Chu WC, et al. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2015; 30: 139-146. doi:10.1111/jgh.12656PMID: 25040896.
34. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158: 825- 830. doi:10.7326/0003-4819-158-11-201306040-00007 PMID: 23732715.
35. Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T. Early change in proteinuria as a surrogate end point for kidney disease progression: An individual patient meta-analysis. Am J Kidney Dis. 2014; 64: 74-85. doi:10.1053/j.ajkd.2014.02.020 PMID: 24787763.
36. Garland JS. Elevated body mass index as a risk factor for chronic kidney disease: current perspectives. Diabetes Metab Syndr Obes. 2014; 7: 347-355. doi:10.2147/DMSO.S46674 PMID: 25114577.
37. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 2011; 7: 456-465. doi:10.1038/nrendo.2011.72 PMID: 21556019.